In order to facilitate angiogenesis, cancer cells frequently overexpress pro‐angiogenic factors, for example, vascular endothelial growth factor‐A (VEGFA), thereby positioning anti‐angiogenic agents as potential strategies for tumor therapy. This evidence concerns the gene VEGFA and neoplasm.